# Single Dose Crossover Comparative Bioavailability and Food Effect Study of Two EMB-001 Formulations

> **NCT03404817** · PHASE1 · COMPLETED · sponsor: **Embera NeuroTherapeutics, Inc.** · enrollment: 9 (actual)

## Conditions studied

- Cocaine Use Disorder

## Interventions

- **DRUG:** Original formulation EMB-001
- **DRUG:** New formulation EMB-001

## Key facts

- **NCT ID:** NCT03404817
- **Lead sponsor:** Embera NeuroTherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-01
- **Primary completion:** 2018-06-07
- **Final completion:** 2018-06-07
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2018-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03404817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03404817, "Single Dose Crossover Comparative Bioavailability and Food Effect Study of Two EMB-001 Formulations". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03404817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*